Bicara Therapeutics (BCAX) Liabilities and Shareholders Equity (2023 - 2026)

Bicara Therapeutics' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $553.6 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 15.8% year-over-year to $553.6 million in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 23.19% increase from a year earlier, with the FY2025 full-year figure at $431.0 million, down 15.49% from the prior year.
• Liabilities and Shareholders Equity advanced to $553.6 million in Q1 2026 per BCAX's latest filing, from $431.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $553.6 million in Q1 2026 and bottomed at $234.0 million in Q4 2023.
• The 4-year median for Liabilities and Shareholders Equity is $465.8 million (2025), against an average of $451.1 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 117.96% in 2024 and retreated 18.98% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $234.0 million in 2023, then soared by 117.96% to $510.0 million in 2024, then declined by 15.49% to $431.0 million in 2025, then increased by 28.45% to $553.6 million in 2026.
• Per Business Quant, the three latest BCAX Liabilities and Shareholders Equity figures stand at $553.6 million (Q1 2026), $431.0 million (Q4 2025), and $424.7 million (Q3 2025).